Mesoblast Limited (MESO) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 12/15/22
Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)GlobeNewsWire • 11/22/22
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022GlobeNewsWire • 11/22/22
Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022GlobeNewsWire • 10/30/22
Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHDGlobeNewsWire • 10/02/22
Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022GlobeNewsWire • 08/30/22
Rexlemestrocel-L to be Highlighted at Maxim's Panel on Late-Stage Advancements in Heart Failure Therapeutics and ManagementGlobeNewsWire • 07/12/22
Operational Highlights and Financial Results for the Period Ended March 31, 2022GlobeNewsWire • 06/01/22
Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast BoardGlobeNewsWire • 03/24/22
Operational Highlights and Financial Results for the Period Ended December 31, 2021GlobeNewsWire • 02/24/22
Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn's Colitis After Direct Injection of Remestemcel-L by ColonoscopyGlobeNewsWire • 02/20/22
Mesoblast to Participate in Edison Group's Global Healthcare “Open House” Virtual Conference From January 25-27th, 2022GlobeNewsWire • 01/24/22
Single Dose of Mesoblast's Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc DiseaseGlobeNewsWire • 01/12/22
Mesoblast Provides Update Following Meeting With FDA's OTAT on Remestemcel-L for Children With Acute Graft Versus Host DiseaseGlobeNewsWire • 12/30/21
FDA's Office Agrees On 12-Month Reduction In Pain As Primary Endpoint For Mesoblast's Back Pain StudyBenzinga • 12/16/21
FDA's OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain ProgramGlobeNewsWire • 12/16/21
Down 35.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Mesoblast Limited (MESO)Zacks Investment Research • 12/15/21